KAT8-IN-1

Cat. No.:	HY-W015239
CAS No.:	605-62-9
Molecular Formula:	$C_{10}H_7NO_3$
Molecular Weight:	189.17
Target:	Others
Pathway:	Others
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (528.63 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	5.2863 mL	26.4313 mL	52.8625 mL
	5 mM	1.0573 mL	5.2863 mL	10.5725 mL
	10 mM	0.5286 mL	2.6431 mL	5.2863 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (13.22 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1 mg/mL (5.29 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

KAT8-IN-1 is a lysine (K) acetyltransferase 8 (KAT8) inhibitor, with IC_{50}s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8 inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases[1].

IC_{50} & Target

IC50: 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B)[1]

In Vitro

KAT8-IN-1 (compound 19) losses anti-oxidant activity (EC_{50}>1 mM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wapenaar H, et al. The relevance of Ki calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor. Eur J Med Chem. 2017 Aug 18;136:480-486.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA